Načítá se...
Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis
BACKGROUND: Recombinant factor VIIa (rFVIIa) has been used off-label as an adjunct in the reversal of warfarin therapy and management of hemorrhage after trauma. Only a handful of these reports are rigorous studies, from which results regarding safety and effectiveness have been mixed. There remains...
Uloženo v:
| Vydáno v: | Trauma Surg Acute Care Open |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5887758/ https://ncbi.nlm.nih.gov/pubmed/29766126 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/tsaco-2017-000134 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|